Last update 27 Mar 2025

YTS-104

Overview

Basic Info

Drug Type
Autologous CAR-T
Synonyms
合成性T细胞受体抗原受体, YTS 104, YTS104
Target
LILRB4
Action
inhibitors
Mechanism
LILRB4 inhibitors(Leukocyte immunoglobulin-like receptor subfamily B member 4 inhibitors)
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [1]
Active Indication
Multiple MyelomaChronic Myelogenous LeukemiaChronic Myelomonocytic Leukemia+ [3]
Inactive Indication-
Originator Organization
BriSTAR Immunotech LimitedBriSTAR Immunotech LimitedStartup
Active Organization
BriSTAR Immunotech LimitedBriSTAR Immunotech LimitedStartup
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Related

3
Clinical Trials associated with YTS-104
NCT05913804
/ Not yet recruitingPhase 1IIT
An Exploratory Clinical Study on the Safety and Efficacy of YTS104 Cell Injection in the Treatment of Relapsed or Refractory Multiple Myeloma
NCT05548088
/ CompletedPhase 1IIT
An Exploratory Clinical Study of the Safety and Efficacy of LILRB4 STAR-T Cells for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia/Chronic Granulocytic-Mononocytic Leukemia
NCT05739409
/ Not yet recruitingNot ApplicableIIT
An Exploratory Clinical Study on the Safety and Efficacy of LILRB4 STAR-T Cells in the Treatment of Monocytic Leukemia
100 Clinical Results associated with YTS-104
Login to view more data
100 Translational Medicine associated with YTS-104
Login to view more data
100 Patents (Medical) associated with YTS-104
Login to view more data
100 Deals associated with YTS-104
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multiple MyelomaPhase 1
China
BriSTAR Immunotech LimitedBriSTAR Immunotech LimitedStartup
15 Jun 2023
Chronic Myelogenous LeukemiaPhase 1
China
-25 May 2023
Chronic Myelomonocytic LeukemiaPhase 1
China
-25 May 2023
Refractory acute myeloid leukemiaPhase 1
China
-25 May 2023
Acute Myeloid LeukemiaPhase 1
China
BriSTAR Immunotech LimitedBriSTAR Immunotech LimitedStartup
-
Relapsing acute myeloid leukemiaIND Application
China
BriSTAR Immunotech LimitedBriSTAR Immunotech LimitedStartup
03 Nov 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free